[Effects of azithromycin on pathogenic bacteria].
Tateda
Kazuhiro
K
Ishii
Yoshikazu
Y
Yamaguchi
Keizo
K
D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D017963:Azithromycin / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000096:biosynthesis; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000096:biosynthesis; D054426:Chemokine CXCL2; D018925:Chemokines / Q000096:biosynthesis; D024881:Drug Resistance, Bacterial; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D006017:Glycolipids / Q000096:biosynthesis; D008264:Macrophages / Q000166:cytology / Q000378:metabolism; D051379:Mice; D010196:Pancreatic Elastase / Q000096:biosynthesis; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D018932:Chemokine CCL2; D054426:Chemokine CXCL2; D018925:Chemokines; C404915:Cxcl2 protein, mouse; D006017:Glycolipids; C418382:rhamnolipid; C088386:homoserine lactone; D017963:Azithromycin; D010196:Pancreatic Elastase; D015107:4-Butyrolactone